Is Intrarosa (Prasterone Vaginal DHEA) Safe While Trying to Conceive?

What Is Intrarosa and Why Would a Woman Trying to Conceive Use It?

Intrarosa is a once-nightly vaginal insert containing prasterone 6.5 mg, a synthetic form of dehydroepiandrosterone (DHEA). The FDA approved it in November 2016 specifically for moderate-to-severe dyspareunia (painful sex) caused by GSM. GSM is most common after menopause, but it can affect women of reproductive age who have low estrogen for any reason.

Women trying to conceive (TTC) who might be prescribed Intrarosa are typically in one of these situations:

• Premature ovarian insufficiency (POI), which affects roughly 1 in 100 women under age 40 and causes hypoestrogenic GSM symptoms while fertility is still possible
• Prolonged lactational amenorrhea following a prior birth, where low estrogen causes vaginal dryness that persists into the next TTC window
• Recovery after cancer treatment that suppressed ovarian function transiently
• Unexplained GSM during the reproductive years

Because sex can be painful, some clinicians prescribe Intrarosa to make intercourse possible during a TTC cycle. The clinical question then becomes: is that safe?

How Prasterone Is Converted in Vaginal Tissue

Prasterone (DHEA) is an androgen precursor. When inserted vaginally, vaginal epithelial cells convert it locally into both androgens (testosterone, androstenedione) and estrogens (estradiol, estrone) through intracrinology. The FDA label for Intrarosa reports that after 12 weeks of nightly use, serum DHEA-S rose from baseline, serum testosterone increased approximately 74% above baseline, and serum estradiol increased approximately 100% above baseline in postmenopausal women. These are measurable systemic hormone changes, not just local effects.

For a woman TTC, that systemic absorption matters because both androgens and estrogens can influence follicular development, luteal function, and early embryo implantation in ways that are not fully understood.

The Evidence Gap Is Real

The trials that led to FDA approval, including the phase III AMETHYST studies, enrolled postmenopausal women exclusively. No published trial has enrolled women of reproductive age using prasterone vaginally while actively attempting conception. Any guidance for TTC women is therefore extrapolated from postmenopausal pharmacokinetic data, animal reproductive toxicology, and general DHEA physiology. This gap is not a reason to panic, but it is a reason to have a specific conversation with your reproductive endocrinologist or OB-GYN before continuing Intrarosa in a TTC cycle.

Pregnancy Safety: What the FDA Label Actually Says

The FDA label for Intrarosa contains explicit language that every TTC woman should know verbatim: "Based on findings from animal reproduction studies and the mechanism of action of prasterone, Intrarosa may cause fetal harm when administered to a pregnant woman."

That sentence does real clinical work. It places Intrarosa in the category of drugs where animal data signal fetal risk and human data are absent, which is the basis for recommending discontinuation when pregnancy is confirmed or when a woman is actively TTC.

What the Animal Data Show

In animal reproductive toxicity studies cited in the FDA label, DHEA caused virilization of female fetuses. DHEA is androgenic, and excess androgen exposure during organogenesis can cause ambiguous genitalia in female offspring. This is a known biological mechanism: the same pathway is implicated in congenital adrenal hyperplasia, where fetal androgen excess causes virilization. Whether the systemic hormone levels achieved with vaginal prasterone dosing in humans are high enough to replicate this effect in a human fetus is genuinely unknown.

No Human Pregnancy Studies Exist

The FDA label states plainly that there are no adequate and well-controlled studies in pregnant women. No prospective pregnancy exposure registry has been published for Intrarosa as of the date of this review. The manufacturer's pharmacovigilance database may collect spontaneous reports of pregnancy exposure, but no cohort data are publicly available. This is an evidence gap, and women deserve to hear that directly.

What Happens If You Conceive While Using Intrarosa?

If you become pregnant while using Intrarosa, stop the medication and contact your OB-GYN or maternal-fetal medicine specialist promptly. You do not need to end the pregnancy based on inadvertent early exposure, but your provider will want to document the exposure, discuss monitoring, and refer you to a teratology information service such as MotherToBaby (part of the Organization of Teratology Information Specialists) for individualized counseling. The risk from brief first-trimester exposure before a woman even knows she is pregnant is unquantified, not definitively established as high.

Lactation: Can You Use Intrarosa While Breastfeeding?

There are no human lactation studies for prasterone vaginal inserts. LactMed, the NIH's drug and lactation database, notes that no published data exist on the excretion of DHEA or its metabolites into human breast milk following vaginal prasterone use, the effects on the breastfed infant, or the effects on milk production. This is a complete data void, not reassuring evidence of safety.

What We Know from General DHEA Physiology

DHEA and its sulfate (DHEA-S) are present in human serum and theoretically could transfer to breast milk, as small lipophilic steroid molecules generally cross into milk to some degree. Estradiol and testosterone, both produced from prasterone's local metabolism, are known to appear in breast milk at low levels under normal physiological conditions. Whether the increment from vaginal prasterone dosing would produce clinically meaningful infant exposure is unknown.

The Milk Supply Question

High-dose estrogen suppresses prolactin and can reduce milk supply. Whether the modest estradiol rise from Intrarosa (approximately doubling of serum estradiol from low postmenopausal levels) would affect milk production in a lactating woman, who has much higher baseline estradiol than a postmenopausal woman, is a separate and unanswered question. Most lactation consultants and reproductive clinicians advise against using Intrarosa while breastfeeding until human data are available.

Trying to Conceive: The Specific Clinical Question

Here is a practical framework for thinking through Intrarosa use across TTC and early pregnancy, organized by clinical scenario. No published guideline from ACOG, ASRM, or The Menopause Society currently addresses prasterone use in TTC women directly. What follows synthesizes FDA label data, general reproductive pharmacology, and the clinical reasoning most reproductive endocrinologists apply.

Scenario 1: GSM Symptoms During Active TTC Cycles

If you are using Intrarosa because dyspareunia is making timed intercourse or natural conception attempts painful or impossible, the clinical calculus is genuinely complicated. Avoiding sex entirely because it hurts defeats the purpose of a TTC cycle. But using a drug with uncharacterized fetal risk during a cycle when conception is the goal also carries uncertainty.

Practical options your clinician might discuss:

• Non-hormonal vaginal moisturizers such as Replens (polycarbophil-based), used regularly rather than just at intercourse, can meaningfully reduce friction and discomfort. ACOG's guidance on GSM management includes these as first-line options.
• Iso-osmolar, fertility-friendly lubricants such as Pre-Seed are compatible with sperm motility and have no known fetal risk when used at intercourse, unlike many standard lubricants.
• Very low-dose vaginal estrogen, such as estradiol vaginal cream 0.01% or vaginal estradiol tablets (Vagifem/Yuvafem), has a longer safety record in reproductive-age women with hypoestrogenism, though human TTC data are also limited. Some reproductive endocrinologists prefer this option over prasterone for TTC patients.
• Stopping Intrarosa two to four weeks before a TTC cycle starts and switching to non-hormonal options is a reasonable middle path if your symptoms are manageable with lubricants alone.

Scenario 2: Unexplained POI with Residual Ovarian Function

Women with POI who still have occasional ovulation cycles and are attempting conception with their own eggs represent a specific high-complexity population. ASRM's guidance on POI does not address Intrarosa specifically. The hypoestrogenic vaginal environment in POI can be severe, and some of these women are prescribed Intrarosa or vaginal estrogen for symptom relief while pursuing fertility treatment. In this scenario, the decision should be made collaboratively with a reproductive endocrinologist who can weigh symptom severity, fertility treatment protocol, and timing.

Scenario 3: IVF Cycles

During in vitro fertilization, the vaginal environment is often medicated anyway, with progesterone suppositories or gel constituting the primary vaginal agent during the luteal support phase. Using Intrarosa simultaneously with vaginal progesterone is not a studied combination. Prasterone's androgenic metabolites could theoretically interact with the endometrium during the implantation window, though no human data confirm or deny this. Most IVF programs would advise stopping Intrarosa before the stimulation phase of a cycle.

Contraception Note for Women Not Yet TTC

If you are using Intrarosa and not yet actively trying to conceive, the FDA label recommends using effective contraception because of the potential for fetal harm. This is not a commonly highlighted warning in GSM treatment discussions, where Intrarosa patients are usually assumed to be postmenopausal, but it is explicit in the prescribing information.

Who Intrarosa Is and Is Not Right for, by Life Stage

Reproductive-Age Women (Roughly Ages 18 to 40)

Intrarosa was not studied in this age group. GSM in reproductive-age women usually signals an underlying hypoestrogenic condition (POI, hypothalamic amenorrhea, lactation, chemotherapy-induced ovarian suppression). Treating the underlying cause of low estrogen, where possible, is preferred over vaginal hormone therapy alone. If Intrarosa is considered for symptom relief, use during TTC cycles should be avoided until more data exist.

Perimenopause

Perimenopausal women still ovulate intermittently and can conceive. If a perimenopausal woman is using Intrarosa and has not yet confirmed she is in confirmed menopause (defined as 12 consecutive months of amenorrhea without another cause), pregnancy remains possible and the FDA contraception warning applies.

Postmenopause

This is the approved indication and the population in whom all safety and efficacy data were gathered. The pregnancy risk is not applicable for confirmed postmenopausal women.

Lactation (Any Age)

Avoid Intrarosa while breastfeeding until human lactation data are available, based on the LactMed assessment of no available evidence and the theoretical possibility of hormone transfer to milk.

What the Systemic Absorption Data Mean for TTC Women

The phase III trials for Intrarosa measured serum hormone levels after 12 weeks of nightly vaginal use in postmenopausal women. Key findings from the AMETHYST trial published in Menopause in 2015 included:

• Serum DHEA-S rose by approximately 3-fold from very low postmenopausal baseline values
• Serum testosterone rose approximately 74% above baseline
• Serum estradiol nearly doubled from postmenopausal levels (roughly 5 pg/mL to 10 pg/mL)

In a reproductive-age woman, baseline hormone levels are far higher than in a postmenopausal woman. The absolute increment from vaginal prasterone might represent a smaller percentage change from baseline. However, whether the absolute concentration achieved, or the specific androgen:estrogen ratio produced, poses a risk during embryogenesis is genuinely not known. Androgen excess during the first trimester is the mechanism behind female fetal virilization in congenital adrenal hyperplasia, which is established human biology, and it is the mechanism the FDA cites when warning about Intrarosa in pregnancy.

Alternatives to Intrarosa for TTC Women with GSM Symptoms

Because Intrarosa's safety profile in TTC women is uncharacterized, knowing your alternatives matters.

Non-Hormonal First-Line Options

Vaginal moisturizers used regularly (every two to three days) are the most evidence-backed non-hormonal approach. A 2018 trial published in JAMA Internal Medicine found that vaginal moisturizer was comparable to low-dose vaginal estrogen for symptom relief in postmenopausal women over 12 weeks, which is the best available proxy for reproductive-age GSM.

Pelvic floor physical therapy addresses dyspareunia that has a musculoskeletal component, which frequently co-exists with hormonal GSM, especially after childbirth or in women with a history of vaginismus.

Low-Dose Vaginal Estrogen as a Potential Alternative

ACOG's clinical practice guideline on GSM from 2022 states that low-dose vaginal estrogen is minimally absorbed systemically and is the most studied hormonal option for GSM. For reproductive-age women with hypoestrogenism, some reproductive endocrinologists prefer low-dose vaginal estradiol over prasterone during TTC because estradiol's pharmacology in early pregnancy is better characterized, even if human TTC safety data are also incomplete for vaginal estrogen products.

Ospemifene: Not for TTC Women

Ospemifene (Osphena), an oral selective estrogen receptor modulator for GSM dyspareunia, is contraindicated in women who could become pregnant because SERMs carry teratogenic risk in animal models and should not be used by women TTC.

A Note on Oral DHEA Supplements and TTC

Women sometimes ask whether oral DHEA supplements, commonly taken at doses of 25 to 75 mg daily to improve ovarian reserve before IVF, are equivalent to Intrarosa. They are not the same intervention. Oral DHEA produces higher systemic hormone levels than vaginal prasterone, and its use in TTC/IVF is a separate, actively researched area. A 2023 Cochrane review on DHEA supplementation for poor ovarian responders found insufficient evidence to support routine use. Neither oral DHEA nor vaginal prasterone has established safety data in TTC women, but the two products have different pharmacokinetics and should not be conflated.

How to Talk with Your Clinician

If you are currently using Intrarosa and are TTC or planning to TTC in the next one to three months, bring these specific questions to your appointment:

1. Should I stop Intrarosa before the TTC cycle starts, and if so, how many days before?
2. What non-hormonal alternatives are appropriate for my vaginal symptoms during TTC?
3. If I conceived in the cycle before I stopped Intrarosa, what monitoring should I have?
4. Is my GSM caused by a treatable underlying condition (low estrogen, POI, other) that should be addressed separately from TTC?
5. If I am pursuing IVF, at what point in the protocol should Intrarosa stop?

Your clinician should document that Intrarosa was prescribed off-label for your life stage and that discontinuation timing was discussed. If you are referred to a reproductive endocrinologist, bring the full list of all vaginal medications, including moisturizers and lubricants, not just the Intrarosa, because medication interactions in the vaginal environment during an IVF cycle matter.

If you are inadvertently pregnant and were using Intrarosa, contact the MotherToBaby teratology service at 1-866-626-6847 or motherisk.org for individualized counseling, and notify your OB-GYN immediately. Do not stop any other medications without provider guidance.